Psoriatic Arthritis, Rheumatoid Arthritis, SARS-CoV-2, Sjogren's Syndrome, Systemic Lupus Erythematosus
Conditions
Keywords
Hydroxychloroquine
Brief summary
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
Interventions
OTHERQuestionnaire by phone call
2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in Suggestive of a COVID-19 infection or Not suggestive of COVID-19 infection by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake.
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of Systemic Lupus Erythematosus, Rheumatoid arthritis, Sjogren's Syndrome or Psoriatic Arthritis.
Exclusion criteria
* beginning, or end, of an hydroxychloroquine treatment between Jan 1, 2020 and day of the phone call. * Bad treatment compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adjusted Odds Ratio | 4 months after inclusion | Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection. |
Countries
France
Outcome results
None listed